The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).
Fatima H Karzai
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
David Adelberg
No relevant relationships to disclose
Ravi A. Madan
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Philip M. Arlen
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
Ann Pierpoint
No relevant relationships to disclose
David R. Kohler
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Douglas K. Price
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose